SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:uu-524848"
 

Search: onr:"swepub:oai:DiVA.org:uu-524848" > Model-based effect ...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Model-based effect evaluation of a novel Mmpl3 inhibitor in C3HeB/FeJ compared to BALB/c mouse models and translation to humans

Ayoun Alsoud, Rami (author)
Uppsala universitet,Institutionen för farmaceutisk biovetenskap,Pharmacokinetics and Quantitative Pharmacology
Keutzer, Lina (author)
Uppsala universitet,Institutionen för farmaceutisk biovetenskap,Pharmacokinetics and Quantitative Pharmacology
Hölscher, Christoph (author)
Division of Infection Immunology, Research Centre Borstel, Leibniz Lung Centre, Borstel, Germany,
show more...
Redinger, Natalja (author)
Division of Cellular Microbiology, Research Centre Borstel, Leibniz Lung Centre, Borstel, Germany
Hölscher, Alexandra (author)
Division of Infection Immunology, Research Centre Borstel, Leibniz Lung Centre, Borstel, Germany
Schaible, Ulrich (author)
Division of Cellular Microbiology, Research Centre Borstel, Leibniz Lung Centre, Borstel, Germany
Bazaga, Santiago Ferrer (author)
Universidad Carlos III de Madrid, Madrid, Spain
Fotouhi, Nader (author)
TB alliance, USA
Serbina, Natalya (author)
TB alliance, USA
Simonsson, Ulrika S. H., Professor (author)
Uppsala universitet,Institutionen för farmaceutisk biovetenskap,Institutionen för farmaci
show less...
 (creator_code:org_t)
English.
  • Other publication (other academic/artistic)
Abstract Subject headings
Close  
  • Background and Purpose: During tuberculosis drug development, the design of early clinical studies is informed by preclinical animal models. The aim of this work was to describe the exposure-response relationship of a novel inhibitor of mycobacterial MmpL3, prodrug MPL-447, in C3HeB/FeJ mice with non-necrotic or necrotic lesions, and to compare to chronic BALB/c mice information.Experimental Approach: C3HeB/FeJ mice were randomised to placebo and three treatment groups (25, 50 or 100 mg/kg MPL-447). Colony forming unit (CFU) were obtained until week 8 post-treatment. Semi-mechanistic modelling was used to describe growth and killing in relation to exposure. Early bactericidal activity after 14 days (EBA0-14) in humans was predicted using the final model, translational factors and allometric scaling of pharmacokinetics to humans and compared to chronic BALB/c.Key Results: The final model showed 1100% growth and 42% killing of the fast-multiplying bacteria in C3HeB/FeJ mice with necrotic lesions compared to those with non-necrotic lesions. Simulations revealed similar log10CFU reduction on day 14 in C3HeB/FeJ mice with non-necrotic lesions as in chronic BALB/c mice in response to treatment, but 1.7-fold lower reduction in C3HeB/FeJ mice with necrotic lesions. Similar human EBA0-14 was predicted irrespective of the mouse model used. Conclusion and Implications:  The difference in killing of fast-multiplying bacteria in C3HeB/FeJ mice with necrotic lesions compared to C3HeB/FeJ mice without or chronic BALB/C mice was not translated to human early clinical predictions, most likely due to low abundance of these bacteria in humans.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Farmaceutiska vetenskaper (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Pharmaceutical Sciences (hsv//eng)

Keyword

BALB/c
C3HeB/FeJ
MmpL3 inhibitor
modelling
tuberculosis
translation
Farmaceutisk vetenskap
Pharmaceutical Science
Farmakokinetik och läkemedelsterapi
Pharmacokinetics and Drug Therapy

Publication and Content Type

vet (subject category)
ovr (subject category)

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view